A detailed history of Coldstream Capital Management Inc transactions in Moderna, Inc. stock. As of the latest transaction made, Coldstream Capital Management Inc holds 3,609 shares of MRNA stock, worth $147,102. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,609
Previous 4,354 17.11%
Holding current value
$147,102
Previous $517,000 53.38%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$63.64 - $125.14 $47,411 - $93,229
-745 Reduced 17.11%
3,609 $241,000
Q2 2024

Aug 07, 2024

BUY
$101.21 - $166.61 $102,323 - $168,442
1,011 Added 30.24%
4,354 $517,000
Q1 2024

May 13, 2024

BUY
$85.37 - $115.44 $57,624 - $77,922
675 Added 25.3%
3,343 $356,000
Q4 2023

Feb 09, 2024

SELL
$69.51 - $104.43 $60,265 - $90,540
-867 Reduced 24.53%
2,668 $265,000
Q3 2023

Nov 02, 2023

BUY
$96.41 - $126.61 $7,423 - $9,748
77 Added 2.23%
3,535 $365,000
Q2 2023

Aug 03, 2023

SELL
$118.5 - $160.53 $29,743 - $40,293
-251 Reduced 6.77%
3,458 $420,000
Q1 2023

May 15, 2023

SELL
$135.66 - $197.02 $63,081 - $91,614
-465 Reduced 11.14%
3,709 $569,000
Q4 2022

Jan 10, 2023

BUY
$118.38 - $210.04 $83,457 - $148,078
705 Added 20.32%
4,174 $0
Q2 2022

Aug 08, 2022

BUY
$117.13 - $176.59 $108,110 - $162,992
923 Added 36.25%
3,469 $496,000
Q2 2022

Aug 08, 2022

SELL
$117.13 - $176.59 $33,382 - $50,328
-285 Reduced 10.07%
2,546 $364,000
Q1 2022

May 11, 2022

BUY
$126.46 - $235.05 $6,196 - $11,517
49 Added 1.76%
2,831 $488,000
Q4 2021

Feb 11, 2022

BUY
$225.82 - $368.51 $628,231 - $1.03 Million
2,782 New
2,782 $707,000
Q3 2021

Nov 12, 2021

SELL
$221.9 - $484.47 $268,277 - $585,724
-1,209 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$129.91 - $234.98 $157,061 - $284,090
1,209 New
1,209 $284,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $15.9B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Coldstream Capital Management Inc Portfolio

Follow Coldstream Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Coldstream Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Coldstream Capital Management Inc with notifications on news.